Well spotted @Gitmo. It seems highly likely that CM9320 is the RCE sepsis IV trial.
That male participants are preferred is explained by the dot point specification: Females must be of non-child bearing potential (surgically sterile or post-menopausal)
That CMAX is in a position to indicate Check-in and Check-out dates suggests that it has had sufficient responses from interested participants to allow it to now specify a trial timeline.
If any immediate adverse effects are experienced these should be known by early October.
Also worthy of note is that with 80 participants each reimbursed at $6,340 the cost of this aspect of the trial to RCE would be $507.2K.
RCE Price at posting:
77.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)